Intervention not reported
TXA given intravenously and orally at a total dose of greater than 3 g pre‐incision and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
3 participants
Low
Intervention not reported
TXA given intravenously at a total dose of 1 g pre‐incision and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given intravenously and intra‐articularly at a total dose of greater than 3 g pre‐incision, intraoperatively and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
3 participants
Low
Change in eGFR · preventing the progression of CKD
1 finding from 1 review
All‐cause death ( · preventing the progression of CKD
It is very uncertain whether metformin changes all‐cause death ( compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with placebo (moderate certainty).
1 finding from 1 review
Withdrew due to intolerance ( · preventing the progression of CKD
Metformin probably leads to higher withdrew due to intolerance ( compared with placebo (moderate certainty).
1 finding from 1 review
Dose tolerability ( · preventing the progression of CKD
1 finding from 1 review
Kidney failure · preventing the progression of CKD
It is very uncertain whether metformin changes kidney failure (median compared with placebo (very low certainty).
1 finding from 1 review
Change in proteinuria (1 year) · preventing the progression of CKD
1 finding from 1 review
Change in burn‐related pruritus (VAS) ( · people with postburn pruritus
Enalapril ointment showed no clear difference in change in burn‐related pruritus (Scoring table for itching) ( compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · people with postburn pruritus
The review found no eligible studies for this question.
1 finding from 1 review
Pain · people with postburn pruritus
The review found no eligible studies for this question.
1 finding from 1 review
Change in burn‐related pruritus (VAS) ( · people with postburn pruritus
Pulsed high‐intensity laser showed no clear difference in change in burn‐related pruritus Itch Severity Scale (ISS) ( compared with placebo laser (moderate certainty).
1 finding from 1 review
Adverse events · people with postburn pruritus
The review found no eligible studies for this question.
1 finding from 1 review
Pain VAS ( · people with postburn pruritus
Pulsed high‐intensity laser showed no clear difference in pain VAS ( compared with placebo laser (moderate certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy may leads to higher grade 3/4 adverse events compared with placebo/observation (low certainty).
1 finding from 1 review
Progression‐free survival · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy probably leads to lower progression‐free survival compared with placebo/observation (moderate certainty).
1 finding from 1 review
Treatment‐related mortality · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy showed no clear difference in treatment‐related mortality compared with placebo/observation (low certainty).
1 finding from 1 review
Treatment discontinuation · people with chronic lymphocytic leukaemia
It is very uncertain whether immunomodulatory drug maintenance therapy changes treatment discontinuation compared with placebo/observation (very low certainty).
1 finding from 1 review